 |
2016-04-09 21:40:21 Is this a ●●●●●●ary or ●●●●●●ent ●●●●●●on? :.●●●●●●●●●●●●●●●●●●tis.●●●●●●er-●●●●●●l.pdf order ●●●●●●one no ●●●●●●●●●●●● Fitch ●●●●●●es the ●●●●●● ●●●●●●ition of MT would ●●●●●●ent a ●●●●●●gic fit ●●●●●● E●●●●●●t's wider ●●●●●●lio of ●●●●●●ies, ●●●●●●ing its ●●●●●●ng A●●●●●● ●●●●●●int. The ●●●●●●●●●●●● of MT is ●●●●●● ●●●●●●vely as it will ●●●●●●e E●●●●●●t's ●●●●●●●●●●●●l ●●●●●●lio, which Fitch ●●●●●●tly views as weak ●●●●●●ve to its ●●●●●● ●●●●●●ic ●●●●●●ss. This is ●●●●●●y ●●●●●●●●●●●● to the fact that E●●●●●●t holds non-●●●●●●g ●●●●●●ons in ●●●●●●n ●●●●●●s ●●●●●●●●●●●●d by ●●●●●●e ●●●●●●ition and ●●●●●●re to macro-●●●●●●d risks. Fitch notes that ●●●●●●gh MT has ●●●●●●ly ●●●●●●enced some ●●●●●●rd trend in ●●●●●●es and EBITDA due to ●●●●●●g ●●●●●●re from ●●●●●●ition and ●●●●●●tory ●●●●●●es in the ●●●●●●ic ●●●●●●, its high EBITDA ●●●●●● and ●●●●●● cash flow ●●●●●●tion are yet ●●●●●● to ●●●●●● in a ●●●●●● ●●●●●●nd flow for E●●●●●●t over the ●●●●●● term. :.●●●●●●●●●●●●●●●●●●-●●●●●●s-50mg-●●●●●●ol.pdf para que serve o ●●●●●●o ●●●●●●ol 25mg The ●●●●●● has ●●●●●● into a rout, at least for now. In state after state, the brand-name ●●●●●●âled by the ●●●●●●●●●●●●al ●●●●●● Amgen and G●●●●●●châhave been ●●●●●● to ●●●●●●ce state ●●●●●●●●●●●● to ●●●●●●e ●●●●●●cists to ●●●●●● ●●●●●●s (and ●●●●●●mes ●●●●●●ts) when they ●●●●●●tute ●●●●●●cs for brand-name ●●●●●●ic drugs. M●●●●●●●●●●●● of ●●●●●● ●●●●●●ly ●●●●●●d such a ●●●●●●ement, which they said would put them at a ●●●●●●itive ●●●●●●●●●●●●. |